Vaccines: How to Use Market-Based Incentives to Ramp Up Production

Economic incentives to accelerate vaccine production would be much more productive than the empty threat of suing AstraZeneca. The additional cost for boosting vaccine supply for Europe might run into a couple of billions of euros, but this would be a lot less than the cost of prolonged disruption to the economy and society, let alone the lives lost. Clemens Fuest and Daniel Gros examine the EU's mistakes.